FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282932731> ?p ?o ?g. }

• W4282932731 abstract "Capmatinib and tepotinib are guideline-recommended front-line treatments for non-small-cell lung cancer (NSCLC) patients with MET exon 14 skipping mutations (METex14). However, the emergence of acquired resistance to capmatinib/tepotinib is almost inevitable partially due to D1228X or Y1230X secondary mutations of the MET. In this study, we explored agents that are active against both D1228X and Y1230X MET to propose an ideal sequential treatment after capmatinib/tepotinib treatment failure in NSCLC patients with METex14.The inhibitory effects of 300 drugs, including 33 MET-TKIs, were screened in Ba/F3 cells carrying METex14 plus MET D1228A/Y secondary mutations. The screen revealed four-candidate type II MET-TKIs (altiratinib, CEP-40783, foretinib and sitravatinib). Therefore, we performed further growth inhibitory assays using these four MET-TKIs plus cabozantinib and merestinib in Ba/F3 cells carrying MET D1228A/E/G/H/N/V/Y or Y1230C/D/H/N/S secondary mutations. We also performed analyses using Hs746t cell models carrying METex14 (with mutant allele amplification) with/without D1228X or Y1230X in vitro and in vivo to confirm the findings. Furthermore, molecular dynamics (MD) simulations were carried out to examine differences in binding between type II MET-TKIs.All 6 type II MET-TKIs were active against Y1230X secondary mutations. However, among these 6 agents, only foretinib showed potent activity against D1228X secondary mutations of the MET in the Ba/F3 cell and Hs746t in vitro model and Hs746t in vivo model, and CEP-40783 and altiratinib demonstrated some activity. MD analysis suggested that the long tail of foretinib plays an important role in binding D1228X MET through interaction with a residue at the solvent front (G1163). Tertiary G1163X mutations, together with L1195F/I and F1200I/L, occurred as acquired resistance mechanisms to the second-line treatment foretinib in Ba/F3 cell models.The type II MET-TKI foretinib may be an appropriate second-line treatment for NSCLCs carrying METex14 after campatinib/tepotinib treatment failure by secondary mutations at residue D1228 or Y1230." @default.
• W4282932731 created "2022-06-16" @default.
• W4282932731 creator A5005624969 @default.
• W4282932731 creator A5009944548 @default.
• W4282932731 creator A5029461288 @default.
• W4282932731 creator A5046100367 @default.
• W4282932731 creator A5049876697 @default.
• W4282932731 creator A5051751383 @default.
• W4282932731 creator A5056573303 @default.
• W4282932731 creator A5058118992 @default.
• W4282932731 creator A5081110935 @default.
• W4282932731 creator A5082519982 @default.
• W4282932731 date "2022-06-11" @default.
• W4282932731 modified "2023-10-18" @default.
• W4282932731 title "Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation" @default.
• W4282932731 cites W1964550379 @default.
• W4282932731 cites W2011284860 @default.
• W4282932731 cites W2017757358 @default.
• W4282932731 cites W2100945326 @default.
• W4282932731 cites W2107763333 @default.
• W4282932731 cites W2111005353 @default.
• W4282932731 cites W2116095691 @default.
• W4282932731 cites W2123706118 @default.
• W4282932731 cites W2290466312 @default.
• W4282932731 cites W2327451947 @default.
• W4282932731 cites W2343845543 @default.
• W4282932731 cites W2475363814 @default.
• W4282932731 cites W2482427906 @default.
• W4282932731 cites W2521720507 @default.
• W4282932731 cites W2526076440 @default.
• W4282932731 cites W2551187851 @default.
• W4282932731 cites W2554557834 @default.
• W4282932731 cites W2605418410 @default.
• W4282932731 cites W2740630940 @default.
• W4282932731 cites W2754451013 @default.
• W4282932731 cites W2767928379 @default.
• W4282932731 cites W2899668190 @default.
• W4282932731 cites W2913265314 @default.
• W4282932731 cites W2943564070 @default.
• W4282932731 cites W2954589648 @default.
• W4282932731 cites W2965436452 @default.
• W4282932731 cites W2977173885 @default.
• W4282932731 cites W2986187229 @default.
• W4282932731 cites W3004655782 @default.
• W4282932731 cites W3007291126 @default.
• W4282932731 cites W3031018272 @default.
• W4282932731 cites W3035839941 @default.
• W4282932731 cites W3039596678 @default.
• W4282932731 cites W3082015854 @default.
• W4282932731 cites W3091637963 @default.
• W4282932731 cites W3137123052 @default.
• W4282932731 cites W3174195119 @default.
• W4282932731 cites W4236481024 @default.
• W4282932731 doi "https://doi.org/10.1186/s13045-022-01299-z" @default.
• W4282932731 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35690785" @default.
• W4282932731 hasPublicationYear "2022" @default.
• W4282932731 type Work @default.
• W4282932731 citedByCount "11" @default.
• W4282932731 countsByYear W42829327312022 @default.
• W4282932731 countsByYear W42829327312023 @default.
• W4282932731 crossrefType "journal-article" @default.
• W4282932731 hasAuthorship W4282932731A5005624969 @default.
• W4282932731 hasAuthorship W4282932731A5009944548 @default.
• W4282932731 hasAuthorship W4282932731A5029461288 @default.
• W4282932731 hasAuthorship W4282932731A5046100367 @default.
• W4282932731 hasAuthorship W4282932731A5049876697 @default.
• W4282932731 hasAuthorship W4282932731A5051751383 @default.
• W4282932731 hasAuthorship W4282932731A5056573303 @default.
• W4282932731 hasAuthorship W4282932731A5058118992 @default.
• W4282932731 hasAuthorship W4282932731A5081110935 @default.
• W4282932731 hasAuthorship W4282932731A5082519982 @default.
• W4282932731 hasBestOaLocation W42829327311 @default.
• W4282932731 hasConcept C104317684 @default.
• W4282932731 hasConcept C121608353 @default.
• W4282932731 hasConcept C126322002 @default.
• W4282932731 hasConcept C143998085 @default.
• W4282932731 hasConcept C207001950 @default.
• W4282932731 hasConcept C2781064419 @default.
• W4282932731 hasConcept C36823959 @default.
• W4282932731 hasConcept C501734568 @default.
• W4282932731 hasConcept C502942594 @default.
• W4282932731 hasConcept C54355233 @default.
• W4282932731 hasConcept C71924100 @default.
• W4282932731 hasConcept C86803240 @default.
• W4282932731 hasConcept C98274493 @default.
• W4282932731 hasConceptScore W4282932731C104317684 @default.
• W4282932731 hasConceptScore W4282932731C121608353 @default.
• W4282932731 hasConceptScore W4282932731C126322002 @default.
• W4282932731 hasConceptScore W4282932731C143998085 @default.
• W4282932731 hasConceptScore W4282932731C207001950 @default.
• W4282932731 hasConceptScore W4282932731C2781064419 @default.
• W4282932731 hasConceptScore W4282932731C36823959 @default.
• W4282932731 hasConceptScore W4282932731C501734568 @default.
• W4282932731 hasConceptScore W4282932731C502942594 @default.
• W4282932731 hasConceptScore W4282932731C54355233 @default.
• W4282932731 hasConceptScore W4282932731C71924100 @default.
• W4282932731 hasConceptScore W4282932731C86803240 @default.
• W4282932731 hasConceptScore W4282932731C98274493 @default.
• W4282932731 hasFunder F4320334764 @default.
• W4282932731 hasIssue "1" @default.

• next